Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biotest highlights positive trends in first half

Biotest highlights positive trends in first half

11th August 2011

Biotest has published its financial results for the first six months of 2011, during which the company saw a 4.9 percent year-on-year sales increase from its continuing operations.

The combined sales total for Biotest's plasma proteins and biotherapeutics divisions came to 212.9 million euros (187.7 million pounds), compared to 202.9 million euros in the corresponding period of 2010.

This increase was attributed primarily to an upfront payment received from Abbott as part of a new development and cooperation agreement focusing on the commercialisation of the monoclonal antibody BT-061.

Biotest states that research and development efforts in its biotherapeutics unit are progressing in line with targets, with the performance of this division helping to offset the challenging conditions faced by its plasma proteins operations.

The report also comes in the same month that Biotest streamlined its business after completing the sale of its microbiological monitoring unit to Merck KGaA.

It expects to achieve low single-digit sales growth compared to 2010 over the full-year period as a result of these developments.ADNFCR-8000103-ID-800696388-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.